The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States
Open accessAbstract
One of the major limitations of the use of adenoviruses as gene therapy vectors is the existence of preformed immunity in various populations. Recent studies have linked failure of adenoviral gene therapy trials to the presence of antiadenoviral neutralizing antibodies (NAb). Understanding the distribution and specificity of such antibodies will assist in the design of successful recombinant adenoviral gene therapies and vaccines. To assess the prevalence of NAb to adenovirus serotypes 5 and 35 (Ad5 and Ad35), we analyzed serum samples from adult immunocompetent individuals living in The Gambia, South Africa, and the United States by using a neutralization assay. Serum samples were incubated with A549 lung carcinoma cells and adenoviruses encoding enhanced green or yellow fluorescent proteins; results were analyzed by fluorescence microscopy and flow cytometry. Using this technique, we found a high prevalence of NAb against Ad5 in Gambian, South African, and U.S. subjects at both low and high titers. Conversely, all subjects displayed a low prevalence of NAb to Ad35; when present, anti-Ad35 NAb were seen at low titers. Because of the ability of adenoviruses to elicit systemic and mucosal immune responses, Ad35 with its low NAb prevalence appears to be an attractive candidate vector for gene therapy applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,411
Manual of Clinical Microbiology, 7th ed.
Balows, A. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00102-9 · Cited by 1,613
Yang, Y., Li, Q., Ertl, H. C., & Wilson, J. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.4.2004-2015.1995 · Cited by 1,032
Construction of adenovirus vectors through Cre-lox recombination
Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., & Phipps, M. L. (1997) · Journal of Virology · doi:10.1128/jvi.71.3.1842-1849.1997 · Cited by 789
Gene Therapy Death Prompts Review of Adenovirus Vector
Marshall, E. (1999) · Science · doi:10.1126/science.286.5448.2244 · Cited by 760
Viral Infections of Humans. Epidemiology and Control.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-2-273_2 · Cited by 749
Vogels, R., Zuijdgeest, D., van Rijnsoever, R., Hartkoorn, E., Damen, I., de Béthune, M.-P., Kostense, S., Penders, G., Helmus, N., Koudstaal, W., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8263-8271.2003 · Cited by 467
Gene therapy: adenovirus vectors
Kozarsky, K. F., & Wilson, J. M. (1993) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(93)90126-a · Cited by 419
Walters, R. W., Grunst, T., Bergelson, J. M., Finberg, R. W., Welsh, M. J., & Zabner, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.15.10219 · Cited by 371
Pickles, R. J., McCarty, D., Matsui, H., Hart, P. J., Randell, S. H., & Boucher, R. C. (1998) · Journal of Virology · doi:10.1128/jvi.72.7.6014-6023.1998 · Cited by 295
Cited by
Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02696-06 · Cited by 503
Gray, G. E., Allen, M., Moodie, Z., Churchyard, G., Bekker, L.-G., Nchabeleng, M., Mlisana, K., Metch, B., de Bruyn, G., Latka, M. H., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70098-6 · Cited by 387
Viruses as vaccine vectors for infectious diseases and cancer
Draper, S. J., & Heeney, J. L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2240 · Cited by 353
Human infection with highly pathogenic H5N1 influenza virus
Gambotto, A., Barratt-Boyes, S. M., de Jong, M. D., Neumann, G., & Kawaoka, Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60627-3 · Cited by 316
Self-citationPre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important?
Fausther-Bovendo, H., & Kobinger, G. P. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29594 · Cited by 276
Metadata
- Authors
- Nwanegbo, E., Vardas, E., Gao, W., Whittle, H., Sun, H., Rowe, D., Robbins, P. D., & Gambotto, A.
- Venue
- Clinical and Vaccine Immunology
- Publisher
- American Society for Microbiology
- Published
- 2004-03
- Volume
- 11
- Issue
- 2
- Pages
- 351-357
- ISSN
- 1556-679X (ISSN-L)
- 1556-6811
- OpenAlex
- W2143749967
- Cited by
- 266
- References
- 31
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States. https://app.cochat.ai/papers/10.1128/cdli.11.2.351-357.2004
- The paper
- Nwanegbo, E., Vardas, E., Gao, W., Whittle, H., Sun, H., Rowe, D., Robbins, P. D., & Gambotto, A. (2004). Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States. Clinical and Vaccine Immunology. https://doi.org/10.1128/cdli.11.2.351-357.2004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.